Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
JOE ANTHONY WARE filed to sell common stock of ANAB through Morgan Stanley Smith Barney LLC Executive Financial Services. The notice covers 10,694 shares of common stock with an aggregate market value of $718,333.09, expected to be sold on or after July 13, 2026 on NASDAQ. The shares relate to a stock option exercise for cash from the issuer. In the preceding three months, 6,030 shares of common stock were sold on June 30, 2026 for total proceeds of $408,773.70.
ANAB affiliate filed a Form 144 reporting a proposed sale of 9,476 shares via a stock option exercise on 06/29/2026, to be effected for cash. The filing also lists multiple common stock dispositions by Dennis Mulroy across May–June 2026, showing transaction dates, share counts, and gross proceeds for each sale.
AnaptysBio, Inc. is asking stockholders to vote at the August 11, 2026 annual meeting on four key items. Stockholders will elect two Class III directors to three-year terms, ratify KPMG LLP as auditor for the fiscal year ending June 30, 2027, and cast an advisory Say‑on‑Pay vote on executive compensation.
The company also seeks approval of an amendment to its 2017 Equity Incentive Plan that extends the plan’s term by 10 years, to June 20, 2036, and adds annual compensation caps for non‑employee directors of $1,000,000 in their first fiscal year of service and $750,000 in later years, starting with fiscal years beginning July 1, 2026. The amendment does not increase the plan’s existing share reserve. As of June 22, 2026, 29,608,481 common shares were outstanding and entitled to vote.
ANAB reports an insider sale activity. The filing lists a stock option exercise to sell 10,000 common shares on 06/26/2026 for cash. The excerpt also lists multiple prior sales by Dennis Mulroy in May–June 2026, including 35,000 shares on 06/11/2026 for $1,848,750 and 20,000 shares on 06/15/2026 for $1,153,014. The transactions are presented as reported sales and proceeds; cash‑flow counterparties and post‑transaction holdings are not specified in the excerpt.
AnaptysBio, Inc. entered into a sublease agreement with First Tracks Biotherapeutics covering approximately 45,057 rentable square feet at 10770 Wateridge Circle in San Diego, space that AnaptysBio leases under an existing master lease.
The sublease began on June 15, 2026 and runs for 12 months, with First Tracks paying the same monthly Basic Rent and Additional Rent that AnaptysBio owes under the master lease, plus charges for any extra services it requests. AnaptysBio remains responsible to the master landlord for all lease obligations while First Tracks agrees to comply with master lease terms.
First Tracks may renew the sublease after the initial term for a period lasting until the earlier of April 4, 2028 or 12 months from the renewal start, and it can terminate at any time with at least three months’ written notice. The sublease is subordinate to the master lease and automatically ends if AnaptysBio’s master lease tenancy or possession ends.
Notice of proposed sale by an insider of common stock. The filing lists 850 common shares to be sold on 06/17/2026 pursuant to a stock option exercise for cash, routed through Morgan Stanley Smith Barney LLC. The excerpt also records numerous prior dispositions by Dennis Mulroy between 05/15/2026 and 06/16/2026, including a 35,000-share sale on 06/11/2026. These entries show transaction dates, share counts, and gross proceeds for each sale.
ANAPTYSBIO director John P. Schmid exercised restricted stock units into common shares. On June 15, 2026 he converted 6,030 RSUs into 6,030 shares of common stock for no cash consideration. Following the transaction, he holds 37,652 common shares directly, with no remaining RSU position reported.